Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 4/20 | 0.68 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.68 |
| ▸ | ELANE | P08246 | 1/20 | 0.66 |
| ▸ | PGAM1 | P18669 | 8/20 | 0.60 |
| ▸ | PKLR | P30613 | 3/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MAOA | P21397 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 2/20 | 0.55 |
| ▸ | DAPK1 | P53355 | 2/20 | 0.55 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30260040 | 1.00 | BCL2 (0.68) | BCL2MCL1ELANEPGAM1PKLR | |
| SCHEMBL18601896 | 0.87 | ELANE (0.59) | BCL2MCL1ELANEPGAM1PKLR | |
| SCHEMBL10909854 | 0.86 | KDM4E (0.55) | BCL2MCL1ELANEPGAM1PKLR | |
| SCHEMBL5573019 | 0.85 | PKLR (0.60) | BCL2MCL1ELANEPGAM1PKLR | |
| SCHEMBL31238107 | 0.83 | ELANE (0.71) | BCL2MCL1ELANEMEN1MAPT | |
| SCHEMBL3192604 | 0.83 | ELANE (0.71) | BCL2MCL1ELANEMEN1MAPT | |
| SCHEMBL3191867 | 0.82 | EPHX2 (0.57) | BCL2MCL1ELANEPGAM1PKLR | |
| SCHEMBL6361693 | 0.82 | EPHX2 (0.67) | BCL2MCL1ELANEPGAM1MEN1 | |
| SCHEMBL29384381 | 0.81 | BCL2 (1.00) | BCL2MCL1ELANEPGAM1PKLR | |
| SCHEMBL555230 | 0.81 | BCL2 (1.00) | BCL2MCL1ELANEPGAM1PKLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111491626-B | Composition for preventing or treating liver cancer comprising 1,2-dihydroxy-3-methylanthraquinone as active ingredient | 加图立大学校产学协力团 | 2023-04-11 | — | — | CN | claimed |
| CN-111491626-A | Composition for preventing or treating liver cancer comprising 1, 2-dihydroxy-3-methylanthraquinone as active ingredient | 加图立大学校产学协力团 | 2020-08-04 | — | — | CN | claimed |
| CN-111491626-B | Composition for preventing or treating liver cancer comprising 1,2-dihydroxy-3-methylanthraquinone as active ingredient | 加图立大学校产学协力团 | 2023-04-11 | — | — | CN | disclosed |
| CN-111491626-B | Composition for preventing or treating liver cancer comprising 1,2-dihydroxy-3-methylanthraquinone as active ingredient | 加图立大学校产学协力团 | 2023-04-11 | — | — | CN | disclosed |
| CN-111491626-B | Composition for preventing or treating liver cancer comprising 1,2-dihydroxy-3-methylanthraquinone as active ingredient | 加图立大学校产学协力团 | 2023-04-11 | — | — | CN | disclosed |
| EP-3050151-B1 | QUINONE AND HYDROQUINONE BASED FLOW BATTERY | HARVARD COLLEGE (US) | 2021-12-15 | — | — | EP | disclosed |
| CN-111491626-A | Composition for preventing or treating liver cancer comprising 1, 2-dihydroxy-3-methylanthraquinone as active ingredient | 加图立大学校产学协力团 | 2020-08-04 | — | — | CN | disclosed |
| CN-111491626-A | Composition for preventing or treating liver cancer comprising 1, 2-dihydroxy-3-methylanthraquinone as active ingredient | 加图立大学校产学协力团 | 2020-08-04 | — | — | CN | disclosed |
| CN-111491626-A | Composition for preventing or treating liver cancer comprising 1, 2-dihydroxy-3-methylanthraquinone as active ingredient | 加图立大学校产学协力团 | 2020-08-04 | — | — | CN | disclosed |
| WO-2019124896-A1 | COMPOSITION CONTAINING 1,2-DIHYDROXY-3-METHYLANTHRAQUINONE AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF LIVER CANCER | 가톨릭대학교산학협력단 | 2019-06-27 | — | — | WO | disclosed |
| US-9938308-B2 | Coordination compounds having redox non-innocent ligands and flow batteries containing the same | LOCKHEED MARTIN ENERGY, LLC (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170291916-A1 | COORDINATION COMPOUNDS HAVING REDOX NON-INNOCENT LIGANDS AND FLOW BATTERIES CONTAINING THE SAME | LOCKHEED MARTIN ENERGY, LLC | 2017-10-12 | — | — | US | disclosed |
| US-20160248114-A1 | QUINONE AND HYDROQUINONE BASED FLOW BATTERY | U.S. DEPARTMENT OF ENERGY | 2016-08-25 | — | — | US | disclosed |
| US-7658937-B2 | Anthraquinones and process for the preparation and method of use thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2010-02-09 | — | — | US | disclosed |
| US-7658937-B2 | Anthraquinones and process for the preparation and method of use thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2010-02-09 | — | — | US | disclosed |
| CN-101638808-A | Method for screening enhanced anti-tumor compounds | UNIV FUDAN | 2010-02-03 | — | — | CN | disclosed |
| WO-2008031358-A1 | 1,2-DIHYDROXY-3-METHYL-9,10-ANTHRAQUINONE IN THE MANUFACTURE OF MEDICAMENTS FOR TREATING CANCERS | FUDAN UNIVERSITY (CN) | 2008-03-20 | — | — | WO | disclosed |
| EP-1745000-A2 | NOVEL ANTHRAQUINONES AND PROCESS FOR THE PREPARATION AND METHOD OF USE THEREOF | Michigan State University (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20050267307-A1 | Novel anthraquinones and process for the preparation and method of use thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2005-12-01 | — | — | US | disclosed |
| WO-2005113478-A2 | NOVEL ANTHRAQUINONES AND PROCESS FOR THE PREPARATION AND METHOD OF USE THEREOF | MICHIGAN STATE UNIVERSITY (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267307-A1 | Novel anthraquinones and process for the preparation and method of use thereof | PAH, APEH, SDHA | BCL2 2400/4885MCL1 1804/4885ELANE 1687/4885 |
| US-20170291916-A1 | COORDINATION COMPOUNDS HAVING REDOX NON-INNOCENT LIGANDS AND FLOW BATTERIES CONTAINING THE SAME | NQO1, VDAC1, SQOR | BCL2 2502/4885MCL1 448/4885ELANE 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.